Spine Biologics Market Analysis

Spine Biologics Market Analysis  

To get key market trends

  Download Free Sample

Based on products, the spine biologics market is segmented into bone grafts, bone graft substitutes, platelet-rich plasma, bone marrow aspirate therapy, and other products. The bone graft segment is further sub-segmented into allografts and autografts. The bone graft substitute segment is further sub-segmented into demineralized bone matrix, synthetic bone grafts, and bone morphogenetic proteins. The bone graft substitutes segment accounted for the largest market share of 64.1% in 2022. In addition to this, it reduces the risk associated with the disease transmission, has osteoconductive properties, osteoinductive potential, and offers the structural integrity and stability.
 

Based on surgery type, the spine biologics market is classified into anterior cervical discectomy and fusion, posterior lumbar interbody fusion, transforaminal lumbar interbody fusion, anterior lumbar interbody fusion, lateral lumbar interbody fusion, and other surgery types. The anterior cervical discectomy and fusion segment was valued at USD 834.9 million in 2022. It is an effective treatment option for relieving pain caused by cervical disc disease. Most patients experience significant pain relief immediately after this surgery. They also help improve the functioning and movement of arms and hands.

Based on end-user, the spine biologics market is sub-divided into hospitals, ambulatory surgical centres, and other end-users. Hospitals segment is expected grow at CAGR of 4.1% by 2032. The hospitals are equipped with comprehensive healthcare facilities, including specialized departments and multidisciplinary teams that can provide a full range of spine care services. This includes diagnostics, surgical interventions, and post-operative care, making hospitals an attractive choice for patients requiring spine biologics. In addition to this, the hospitals typically have established relationships with insurance providers and can facilitate insurance coverage and reimbursement processes for patients undergoing spine biologics procedures. This industry it easier for patients to access and afford these treatments.

Based on the region, North America spine biologics market is expected to reach USD 1.4 billion by 2032. The region has a relatively high prevalence of spinal conditions, such as degenerative disc disease, spinal stenosis, and spinal deformities. This results in a significant patient pool for surgical interventions, such as the use of spine biologics. In addition to this, North America has a well-developed healthcare system, presence of prominent players in this business, and increased awareness and demand for minimally invasive procedures.